Skip to content

SNO 2022: Chimerix-Sponsored Independent Supported Session
The ACTION study - A Phase 3 Trial of ONC201 in H3 K27M-mutant Diffuse Glioma

Saturday, November 19th, 12:45-2:15pm
Tampa Bay Convention Center, Rooms 120 & 121

1.Will you be able to join us for our Independent Supported Session?(Required.)
2.Attendee Name(Required.)
3.Email Address(Required.)
4.Attendee Institution (name of hospital, university, organization, etc)
5.Are you familiar with ONC201 in H3 K27M-mutant diffuse glioma?
6.Please let us know if you have any questions about ONC201 or the Phase 3 ACTION Trial:
The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Independent Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.